Date published: 2026-5-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

KLHL8 Inhibitors

KLHL8 inhibitors belong to a specific class of chemical compounds that target the Kelch-like protein 8 (KLHL8), a substrate adaptor for the Cullin3 (CUL3)-dependent E3 ubiquitin ligase complex. The KLHL8 protein is involved in the regulation of various cellular processes, particularly the ubiquitination and subsequent degradation of specific protein substrates. Inhibitors of KLHL8 are designed to interfere with this ubiquitin-proteasome system, modulating the degradation of target proteins implicated in diverse cellular functions. The structural basis of KLHL8 inhibition lies in the binding of these inhibitors to the Kelch domain of the KLHL8 protein, disrupting its interaction with substrate proteins and thereby preventing their ubiquitination.

The development of KLHL8 inhibitors stems from a growing interest in understanding the intricacies of the ubiquitin-proteasome system and its role in cellular homeostasis. Researchers aim to unravel the specific substrates targeted by KLHL8 and elucidate the downstream cellular pathways affected by its inhibition. By dissecting the molecular mechanisms underlying KLHL8 inhibition, scientists seek to gain insights into the broader regulatory networks governing cellular processes such as signal transduction, protein stability, and cellular response to various stimuli.

SEE ALSO...

Items 11 to 12 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Mitomycin C

50-07-7sc-3514A
sc-3514
sc-3514B
2 mg
5 mg
10 mg
$66.00
$101.00
$143.00
85
(5)

Mitomycin C is an alkylating agent that crosslinks DNA, leading to inhibition of DNA synthesis and cell division. As KLHL8 is involved in cellular proliferation, its activity could be indirectly decreased by preventing cell cycle progression.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Bortezomib is a proteasome inhibitor used to disrupt the degradation of ubiquitinated proteins. As with other proteasome inhibitors, the effect on ubiquitin-proteasome pathways can indirectly inhibit KLHL8 through the accumulation of polyubiquitinated proteins.